论文部分内容阅读
经美国国家卫生院(NIH)批准,Genentech公司进行了TPA(tissue plasminogen activator,血纤蛋白溶酶原激活剂)的试验。试验报告说,TPA能溶解三分之二以上心脏病患者的凝块;而通常使用的链激酶(St-eptokinase)只能溶解37％病人的凝块。
Approved by the National Institutes of Health (NIH), Genentech conducted a TPA (tissue plasminogen activator) test. According to the trial, TPA can dissolve more than two-thirds of patients with heart disease, whereas commonly used St-eptokinase can only dissolve 37% of patients with clots.